Sudden Sight Loss Risks with Semaglutide Weight Loss Drugs

A new study finds that Wegovy users have nearly 5 times the risk of sudden sight loss compared to Ozempic users, likely due to the active ingredient semaglutide.

Semaglutide-Based Drugs Linked to 5x Higher Sudden Sight Loss Risk

A large-scale study has found that patients taking the weight loss drug Wegovy have nearly five times the risk of sudden sight loss compared to those taking Ozempic, another semaglutide-based medication. The research, published in the British Journal of Ophthalmology, suggests that the active ingredient semaglutide may be the culprit behind these

Semaglutide-Based Drugs Linked to 5x Higher Sudden Sight Loss Risk

Comments (0)

Related Articles

Repurposed Drug May Boost Survival in Aggressive Ovarian Cancer

Doctors' Leader Blames Reduced Pay Offer for Ongoing Strikes in England

Groundbreaking Access Consortium Launches Pilot Program